Peters M - Search Results

1

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.

van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME, Smiers FJ, Khair K, Petrini P, Jiménez-Yuste V, Hay CR, van der Bom JG, Yee TT, Fijnvandraat K; INSIGHT study group. van Velzen AS, et al. Among authors: peters m. Thromb Haemost. 2015 Jul;114(1):46-55. doi: 10.1160/TH14-11-0940. Epub 2015 Apr 16. Thromb Haemost. 2015. PMID: 25879247

2

Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way.

Hennis BC, Boomsma DI, Fijnvandraat K, Gevers Leuven JA, Peters M, Kluft C. Hennis BC, et al. Among authors: peters m. Thromb Haemost. 1995 Mar;73(3):484-7. Thromb Haemost. 1995. PMID: 7667832 Clinical Trial.

3

Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality.

Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJ, ten Cate JW. Fijnvandraat K, et al. Among authors: peters m. Thromb Haemost. 1995 Jan;73(1):15-20. Thromb Haemost. 1995. PMID: 7740486

4

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels.

Fijnvandraat K, Peters M, ten Cate JW. Fijnvandraat K, et al. Among authors: peters m. Br J Haematol. 1995 Oct;91(2):474-6. doi: 10.1111/j.1365-2141.1995.tb05325.x. Br J Haematol. 1995. PMID: 8547097 Clinical Trial.

5

Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock.

Wuillemin WA, Fijnvandraat K, Derkx BH, Peters M, Vreede W, ten Cate H, Hack CE. Wuillemin WA, et al. Among authors: peters m. Thromb Haemost. 1995 Dec;74(6):1436-41. Thromb Haemost. 1995. PMID: 8772216

6

Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.

Fijnvandraat K, Berntorp E, ten Cate JW, Johnsson H, Peters M, Savidge G, Tengborn L, Spira J, Stahl C. Fijnvandraat K, et al. Among authors: peters m. Thromb Haemost. 1997 Feb;77(2):298-302. Thromb Haemost. 1997. PMID: 9157585 Clinical Trial.

7

A human alloantibody interferes with binding of factor IXa to the factor VIII light chain.

Fijnvandraat K, Celie PH, Turenhout EA, ten Cate JW, van Mourik JA, Mertens K, Peters M, Voorberg J. Fijnvandraat K, et al. Among authors: peters m. Blood. 1998 Apr 1;91(7):2347-52. Blood. 1998. PMID: 9516133 Free article.

8

Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.

van den Brink EN, Timmermans SM, Turenhout EA, Bank CM, Fijnvandraat K, Voorberg J, Peters M. van den Brink EN, et al. Among authors: peters m. Thromb Haemost. 1999 May;81(5):723-6. Thromb Haemost. 1999. PMID: 10365744

9

Acquired protein S deficiency caused by estrogen treatment of tall stature.

van Ommen CH, Fijnvandraat K, Vulsma T, Delemarre-Van De Waal HA, Peters M. van Ommen CH, et al. Among authors: peters m. J Pediatr. 1999 Oct;135(4):477-81. doi: 10.1016/s0022-3476(99)70171-x. J Pediatr. 1999. PMID: 10518082

10

Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes.

van Den Brink EN, Turenhout EA, Davies J, Bovenschen N, Fijnvandraat K, Ouwehand WH, Peters M, Voorberg J. van Den Brink EN, et al. Among authors: peters m. Blood. 2000 Jan 15;95(2):558-63. Blood. 2000. PMID: 10627462 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,168 results

Search Page

Filters